CompletedPhase 3NCT02578641

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Tessa Therapeutics
Principal Investigator: Han Chong TOH
National Cancer Centre Singapore (NCCS)
Intervention: autologous EBV specific Cytotoxic T cells(biological)
Enrollment: 330 target
Eligibility: 18 years · All sexes
Timeline: 2014 – 2022

Study locations (30)

City of Hope National Medical Center, Duarte, California, United States
University of California Davis Health, Sacramento, California, United States
UCSF HDF Comprehensive Cancer Center, San Francisco, California, United States
Stanford Cancer Center, Stanford, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Baylor Scott & White, Dallas, Texas, United States
Baylor College of Medicine, Houston, Texas, United States
Site MY-03, George Town, Pulau Pinang, Malaysia
Site MY-06, George Town, Pulau Pinang, Malaysia
Site MY-07, Johor Bahru, Malaysia
Site MY-01, Kuala Lumpur, Malaysia
Site MY-04, Kuala Lumpur, Malaysia
Site MY-05, Kuala Lumpur, Malaysia
Site MY-08, Kuala Lumpur, Malaysia
Site SG-11, Singapore, Singapore
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02578641 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials